Shruti Lal

Employment

• Nutcracker Therapeutics Inc Principal Scientist
  2022 - Present

Education

• University of California, Riverside Molecular Genetics
  2007 - 2011

Projects & Funding

Projects & funding information is unavailable.

Publications (17)

• Data from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.c.6782042.v1
  +Save
• Table S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912669
  +Save
• Supplementary Methods from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912672.v1
  +Save
• Figure S6 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912675.v1
  +Save
• Figure S5 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912678.v1
  +Save
• Figure S4 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912681.v1
  +Save
• Figure S3 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912684.v1
  +Save
• Figure S2 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912687.v1
  +Save
• Figure S1 from Discovery and characterization of ZL-2201, a potent, highly selective, and orally bioavailable small-molecule DNA-PK inhibitor
  2023 DOI: 10.1158/2767-9764.23912690.v1
  +Save
• Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
  Cancer Research Communications 2023 DOI: 10.1158/2767-9764.CRC-23-0304
  +Save